82 related articles for article (PubMed ID: 21137246)
1. [Evaluation of risk of progression of endometrial hyperplasia in patients with metabolic syndrome].
Bochkareva NV; Kolomiets LA; Chernyshova AL; Stukanov SL; Savenkova OV
Vopr Onkol; 2010; 56(5):617-22. PubMed ID: 21137246
[TBL] [Abstract][Full Text] [Related]
2. PTEN expression in endometrial hyperplasia and risk of cancer: a systematic review and meta-analysis.
Raffone A; Travaglino A; Saccone G; Viggiani M; Giampaolino P; Insabato L; Mollo A; De Placido G; Zullo F
Arch Gynecol Obstet; 2019 Jun; 299(6):1511-1524. PubMed ID: 30915635
[TBL] [Abstract][Full Text] [Related]
3. Lack of PTEN expression in endometrial intraepithelial neoplasia is correlated with cancer progression.
Baak JP; Van Diermen B; Steinbakk A; Janssen E; Skaland I; Mutter GL; Fiane B; Løvslett K
Hum Pathol; 2005 May; 36(5):555-61. PubMed ID: 15948123
[TBL] [Abstract][Full Text] [Related]
4. Expression of miRNAs and PTEN in endometrial specimens ranging from histologically normal to hyperplasia and endometrial adenocarcinoma.
Lee H; Choi HJ; Kang CS; Lee HJ; Lee WS; Park CS
Mod Pathol; 2012 Nov; 25(11):1508-15. PubMed ID: 22766795
[TBL] [Abstract][Full Text] [Related]
5. PTEN as a predictive marker of response to conservative treatment in endometrial hyperplasia and early endometrial cancer. A systematic review and meta-analysis.
Travaglino A; Raffone A; Saccone G; Insabato L; Mollo A; De Placido G; Zullo F
Eur J Obstet Gynecol Reprod Biol; 2018 Dec; 231():104-110. PubMed ID: 30342311
[TBL] [Abstract][Full Text] [Related]
6. Folate receptor α expression and significance in endometrioid endometrium carcinoma and endometrial hyperplasia.
Senol S; Ceyran AB; Aydin A; Zemheri E; Ozkanli S; Kösemetin D; Sehitoglu I; Akalin I
Int J Clin Exp Pathol; 2015; 8(5):5633-41. PubMed ID: 26191275
[TBL] [Abstract][Full Text] [Related]
7. Case-control study of the metabolic syndrome and metabolic risk factors for endometrial cancer.
Friedenreich CM; Biel RK; Lau DC; Csizmadi I; Courneya KS; Magliocco AM; Yasui Y; Cook LS
Cancer Epidemiol Biomarkers Prev; 2011 Nov; 20(11):2384-95. PubMed ID: 21921255
[TBL] [Abstract][Full Text] [Related]
8. Detection of PTEN immunoreactivity in endometrial hyperplasia and adenocarcinoma.
Tantbirojn P; Triratanachat S; Trivijitsilp P; Niruthisard S
J Med Assoc Thai; 2008 Aug; 91(8):1161-5. PubMed ID: 18788685
[TBL] [Abstract][Full Text] [Related]
9. Prognostic markers for coexistent carcinoma in high-risk endometrial hyperplasia with negative D-score: significance of morphometry, hormone receptors and apoptosis for outcome prediction.
Ørbo A; Kaino T; Arnes M; Larsen K; Pettersen I; Moe B
Acta Obstet Gynecol Scand; 2009; 88(11):1234-42. PubMed ID: 19900140
[TBL] [Abstract][Full Text] [Related]
10. [PTEN coding product: a marker for tumorigenesis and progression of endometrial carcinoma].
Gao QL; Ye F; Li J; Xing H; Lu YP; Ma D
Ai Zheng; 2003 Jun; 22(6):640-4. PubMed ID: 12948417
[TBL] [Abstract][Full Text] [Related]
11. Utility of PTEN expression of endometrial "surface epithelial changes" and underlying atypical endometrial hyperplasia.
Quddus MR; Ologun BA; Sung CJ; Steinhoff MM; Lawrence WD
Int J Gynecol Pathol; 2009 Sep; 28(5):471-6. PubMed ID: 19696618
[TBL] [Abstract][Full Text] [Related]
12. Relation of metabolic syndrome with endometrial pathologies in patients with abnormal uterine bleeding.
Özdemir S; Batmaz G; Ates S; Celik C; Incesu F; Peru C
Gynecol Endocrinol; 2015; 31(9):725-9. PubMed ID: 26182187
[TBL] [Abstract][Full Text] [Related]
13. [Immunohistochemical expression of PTEN antigen: a new tool for diagnosis of early endometrial neoplasia].
Taranger-Charpin C; Carpentier S; Dales JP; Garcia S; Djemli A; Andrac L; Lavaut MN; Sferlazzo K; Boubli L
Bull Acad Natl Med; 2004; 188(3):415-27; discussion 427-9. PubMed ID: 15584653
[TBL] [Abstract][Full Text] [Related]
14. Molecular analysis of endometrial hyperplasia in HNPCC-suspicious patients may predict progression to endometrial carcinoma.
Sutter C; Dallenbach-Hellweg G; Schmidt D; Baehring J; Bielau S; von Knebel Doeberitz M; Gebert J
Int J Gynecol Pathol; 2004 Jan; 23(1):18-25. PubMed ID: 14668545
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical expression of PTEN in normal, hyperplastic and malignant endometrium and its correlation with hormone receptors, bcl-2, bax, and apoptotic index.
Kapucuoglu N; Aktepe F; Kaya H; Bircan S; Karahan N; Ciriş M
Pathol Res Pract; 2007; 203(3):153-62. PubMed ID: 17317031
[TBL] [Abstract][Full Text] [Related]
16. The discriminative ability of waist circumference, body mass index and waist-to-hip ratio in identifying metabolic syndrome: Variations by age, sex and race.
Cheong KC; Ghazali SM; Hock LK; Subenthiran S; Huey TC; Kuay LK; Mustapha FI; Yusoff AF; Mustafa AN
Diabetes Metab Syndr; 2015; 9(2):74-8. PubMed ID: 25819369
[TBL] [Abstract][Full Text] [Related]
17. PTEN-loss and nuclear atypia of EIN in endometrial biopsies can predict the existence of a concurrent endometrial carcinoma.
Pavlakis K; Messini I; Vrekoussis T; Panoskaltsis T; Chrissanthakis D; Yiannou P; Stathopoulos EN
Gynecol Oncol; 2010 Dec; 119(3):516-9. PubMed ID: 20833413
[TBL] [Abstract][Full Text] [Related]
18. An estrogen-induced endometrial hyperplasia mouse model recapitulating human disease progression and genetic aberrations.
Yang CH; Almomen A; Wee YS; Jarboe EA; Peterson CM; Janát-Amsbury MM
Cancer Med; 2015 Jul; 4(7):1039-50. PubMed ID: 25809780
[TBL] [Abstract][Full Text] [Related]
19. Factors predictive of endometrial carcinoma in patients with atypical endometrial hyperplasia on preoperative histology.
Touboul C; Piel B; Koskas M; Gonthier C; Ballester M; Cortez A; Daraï E
Anticancer Res; 2014 Oct; 34(10):5671-6. PubMed ID: 25275072
[TBL] [Abstract][Full Text] [Related]
20. Endometrial hyperplasia and the risk of progression to carcinoma.
Lacey JV; Chia VM
Maturitas; 2009 May; 63(1):39-44. PubMed ID: 19285814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
